Comparison Of Two Anti Depressant Drugs In Major Depressive Disorder

To Compare The Efficacy And Safety Of Escitalopram & Vilazodone In Major Depressive Disorder

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/02/011662

Enrollment

Registered

2018-02-02

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Major Depressive Disorder

Interventions

Intervention1: Vilazodone (20mg): given once daily orally to patients for a period of 6 weeks Control Intervention1: Escitalopram (10mg): given once daily orally to patients for a period of 6 weeks

Eligibility

Inclusion criteria

Inclusion criteria: newly diagnosed patients who meet the DSM 5 criteria for depression

Exclusion criteria

Exclusion criteria: (i) severe comorbid conditions like diabetes, hypertension & ischemic heart disease (ii) patients taking antidepressans in the last 6 weeks (iii) pregnant or lactating females (iv) intake of other drugs for psychosis or anxiety (v) history of substance abuse (vi) any chronic ailment or drug intake leading to depression (vii)) patients with neurological disorders such as stroke, dementia or seizures.

Design outcomes

Primary

Measure	Time frame
HAM A & HAM D scoresTimepoint: Baseline, 3 Weeks & 6 Weeks	—

Secondary

Measure	Time frame
not applicableTimepoint: not applicable	—

Countries

India

Contacts

Public ContactBrij Mohan Gupta

Government Medical College, Jammu

vijaykhaj@yahoo.co.in01912451935

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026